The latest Business updates from the science industry
by Gwyneth Astles
Exclusive partnership unlocks premium antibody access in the UK & Ireland
Europa Biosite is proud to announce a strategic new partnership that will give researchers across the UK and Ireland streamlined access to best-in-class functional monoclonal antibodies.
Bio X Cell has selected Cambridge Bioscience, a longstanding member of the Europa Biosite network, as its exclusive distributor in the region.
This collaboration combines Bio X Cell’s globally recognised portfolio - renowned for exceptional quality, purity, and consistency in in vivo, ex vivo, and emerging research methods - with Cambridge Bioscience’s four decades of expertise in life science distribution.
Their established relationships with leading academic institutions, including
Illustration of a monoclonal antibody. the University of Cambridge, University of Oxford,
University College London, and Trinity College Dublin, make them an ideal partner to support cutting-edge research.
Sune Schmolker, CEO of Europa Biosite, said: “Expanding our collaboration to the UK and Ireland strengthens our mission to provide researchers with the highest-quality reagents and unparalleled support. This exclusive agreement is a testament to the trust and shared commitment between our organisations.”
Christopher Conway, CEO of Bio X Cell, added: “Partnering with Cambridge Bioscience allows us to better serve the scientifi c community in the UK and Ireland. Their customer-focused approach ensures researchers have the resources and support needed to advance critical biomedical studies worldwide.”
For further details on Bio X Cell’s products and to explore the UK & Ireland distribution partnership, please visit the website.
More information online:
ilmt.co/PL/nXw0 65704pr@reply-direct.com
New centre to transform early discoveries into future medicines
Lieberman, a leading authority on Epstein-Barr virus and other cancer-causing viruses, envisions
the centre as a hub for
transforming early biomedical fi ndings into viable therapeutic candidates. “The goal is to create something impactful at Wistar,” he said. “By linking biology, chemistry and development expertise, we can accelerate the path from discovery to patient care and help overcome the drug development ‘Valley of Death’.”
The centre will recruit fi ve new principal investigators over the next two years and expand its team of computational chemists and biologists to accelerate target identifi cation and drug design. Current Wistar experts contributing to the effort include Joseph Salvino, PhD (medicinal chemistry), Troy Messick, PhD (structural biology), and
Dr Paul Lieberman. Credit: The Wistar Institute
The Wistar Institute has launched its new Center for Advanced Therapeutics (CAT) to fast-track early-stage discoveries into opportunities that can be developed into future medicines. Led by Paul Lieberman, PhD, the centre will build on Wistar’s legacy in cancer, immunology and infectious disease by uniting chemists, biologists and industry partners to bridge the gap between basic research and clinical application.
“Despite major progress in treating cancer and other diseases, there is still an urgent need for innovation and collaboration to deliver the next generation of therapies,” said Dario Altieri, MD, Wistar President and CEO. “This centre will act as a catalyst for multidisciplinary discovery and help translate new insights into promising treatments.”
Dr Samantha Soldan. Credit: The Wistar Institute
Samantha Soldan, PhD (autoimmune disease research). Business development efforts will be led by Heather Steinman, PhD, MBA, to strengthen public-private partnerships across the region.
The initiative is supported by a record $30 million anonymous gift and a $1 million grant from The Pew Charitable Trusts, providing resources to establish the centre and recruit top talent. Occupying 12,000 ft2 of newly renovated space at Wistar’s Spruce Street campus, the CAT is Wistar’s second major new centre to open in 2025, following the HIV Cure and Viral Diseases Center launched earlier this year.
Dr Troy Messick. Credit: The Wistar Institute
More information online:
ilmt.co/PL/6D6b and
ilmt.co/PL/9Oe6 65836pr@reply-direct.com
$10,000 grant to help scientists upgrade their lab workflows
Researchers have the chance to secure $10,000* worth of advanced pipetting and automation equipment through the Future Lab Grant from Integra Biosciences. The initiative invites laboratories to rethink how they work and design a set-up that enhances precision, productivity, and ease of use.
The winning lab will collaborate with Integra’s specialists to build a customised workflow using the company’s range of ergonomic
pipettes, multichannel dispensers, and compact automation platforms. Ten runners-up will also receive tailored product recommendations and an exclusive discount to support their 2026 research goals.
To apply, scientists are asked to complete a short questionnaire describing their lab’s biggest operational challenge and how Integra technology could help address it. Entries close on 31
December 2025, and the winner will be announced in January 2026.
More information online:
ilmt.co/PL/GjlY *Prize excludes consumables.
65935pr@reply-direct.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64
